Cargando…

Survival Factors and Metabolic Pathogenesis in Elderly Patients (≥65) With COVID-19: A Multi-Center Study

Background: Elderly patients infected with COVID-19 are reported to be facing a substantially increased risk of mortality. Clinical characteristics, treatment options, and potential survival factors remain under investigation. This study aimed to fill this gap and provide clinically relevant factors...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei, Qi, Wang, Amanda Y., Bryant, Amy, Yang, Yang, Li, Ming, Wang, Fei, Du, Shangming, Kurts, Christian, Wu, Patrick, Ma, Ke, Wu, Liang, Chen, Huawen, Luo, Jinlong, Li, Yong, Hu, Guangyuan, Yuan, Xianglin, Li, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873923/
https://www.ncbi.nlm.nih.gov/pubmed/33585504
http://dx.doi.org/10.3389/fmed.2020.595503
_version_ 1783649477745180672
author Mei, Qi
Wang, Amanda Y.
Bryant, Amy
Yang, Yang
Li, Ming
Wang, Fei
Du, Shangming
Kurts, Christian
Wu, Patrick
Ma, Ke
Wu, Liang
Chen, Huawen
Luo, Jinlong
Li, Yong
Hu, Guangyuan
Yuan, Xianglin
Li, Jian
author_facet Mei, Qi
Wang, Amanda Y.
Bryant, Amy
Yang, Yang
Li, Ming
Wang, Fei
Du, Shangming
Kurts, Christian
Wu, Patrick
Ma, Ke
Wu, Liang
Chen, Huawen
Luo, Jinlong
Li, Yong
Hu, Guangyuan
Yuan, Xianglin
Li, Jian
author_sort Mei, Qi
collection PubMed
description Background: Elderly patients infected with COVID-19 are reported to be facing a substantially increased risk of mortality. Clinical characteristics, treatment options, and potential survival factors remain under investigation. This study aimed to fill this gap and provide clinically relevant factors associated with survival of elderly patients with COVID-19. Methods: In this multi-center study, elderly patients (age ≥65 years old) with laboratory-confirmed COVID-19 from 4 Wuhan hospitals were included. The clinical end point was hospital discharge or deceased with last date of follow-up on Jul. 08, 2020. Clinical, demographic, and laboratory data were collected. Univariate and multivariate analysis were performed to analyze survival and risk factors. A metabolic flux analysis using a large-scale molecular model was applied to investigate the pathogenesis of SARS-CoV-2 with regard to metabolism pathways. Results: A total of 223 elderly patients infected with COVID-19 were included, 91 (40.8%) were discharged and 132 (59.2%) deceased. Acute respiratory distress syndrome (ARDS) developed in 140 (62.8%) patients, 23 (25.3%) of these patients survived. Multivariate analysis showed that potential risk factors for mortality were elevated D-Dimer (odds ratio: 1.13 [95% CI 1.04 - 1.22], p = 0.005), high immune-related metabolic index (6.42 [95% CI 2.66–15.48], p < 0.001), and increased neutrophil-to-lymphocyte ratio (1.08 [95% 1.03–1.13], p < 0.001). Elderly patients receiving interferon atmotherapy showed an increased probability of survival (0.29 [95% CI 0.17–0.51], p < 0.001). Based on these factors, an algorithm (AlgSurv) was developed to predict survival for elderly patients. The metabolic flux analysis showed that 12 metabolic pathways including phenylalanine (odds ratio: 28.27 [95% CI 10.56–75.72], p < 0.001), fatty acid (15.61 [95% CI 6.66–36.6], p < 0.001), and pyruvate (12.86 [95% CI 5.85–28.28], p < 0.001) showed a consistently lower flux in the survivors vs. the deceased subgroup. This may reflect a key pathogenic mechanism of COVID-19 infection. Conclusion: Several factors such as interferon atmotherapy and recreased activity of specific metabolic pathways were found to be associated with survival of elderly patients. Based on these findings, a survival algorithm (AlgSurv) was developed to assist the clinical stratification for elderly patients. Dysregulation of the metabolic pathways revealed in this study may aid in the drug and vaccine development against COVID-19.
format Online
Article
Text
id pubmed-7873923
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78739232021-02-11 Survival Factors and Metabolic Pathogenesis in Elderly Patients (≥65) With COVID-19: A Multi-Center Study Mei, Qi Wang, Amanda Y. Bryant, Amy Yang, Yang Li, Ming Wang, Fei Du, Shangming Kurts, Christian Wu, Patrick Ma, Ke Wu, Liang Chen, Huawen Luo, Jinlong Li, Yong Hu, Guangyuan Yuan, Xianglin Li, Jian Front Med (Lausanne) Medicine Background: Elderly patients infected with COVID-19 are reported to be facing a substantially increased risk of mortality. Clinical characteristics, treatment options, and potential survival factors remain under investigation. This study aimed to fill this gap and provide clinically relevant factors associated with survival of elderly patients with COVID-19. Methods: In this multi-center study, elderly patients (age ≥65 years old) with laboratory-confirmed COVID-19 from 4 Wuhan hospitals were included. The clinical end point was hospital discharge or deceased with last date of follow-up on Jul. 08, 2020. Clinical, demographic, and laboratory data were collected. Univariate and multivariate analysis were performed to analyze survival and risk factors. A metabolic flux analysis using a large-scale molecular model was applied to investigate the pathogenesis of SARS-CoV-2 with regard to metabolism pathways. Results: A total of 223 elderly patients infected with COVID-19 were included, 91 (40.8%) were discharged and 132 (59.2%) deceased. Acute respiratory distress syndrome (ARDS) developed in 140 (62.8%) patients, 23 (25.3%) of these patients survived. Multivariate analysis showed that potential risk factors for mortality were elevated D-Dimer (odds ratio: 1.13 [95% CI 1.04 - 1.22], p = 0.005), high immune-related metabolic index (6.42 [95% CI 2.66–15.48], p < 0.001), and increased neutrophil-to-lymphocyte ratio (1.08 [95% 1.03–1.13], p < 0.001). Elderly patients receiving interferon atmotherapy showed an increased probability of survival (0.29 [95% CI 0.17–0.51], p < 0.001). Based on these factors, an algorithm (AlgSurv) was developed to predict survival for elderly patients. The metabolic flux analysis showed that 12 metabolic pathways including phenylalanine (odds ratio: 28.27 [95% CI 10.56–75.72], p < 0.001), fatty acid (15.61 [95% CI 6.66–36.6], p < 0.001), and pyruvate (12.86 [95% CI 5.85–28.28], p < 0.001) showed a consistently lower flux in the survivors vs. the deceased subgroup. This may reflect a key pathogenic mechanism of COVID-19 infection. Conclusion: Several factors such as interferon atmotherapy and recreased activity of specific metabolic pathways were found to be associated with survival of elderly patients. Based on these findings, a survival algorithm (AlgSurv) was developed to assist the clinical stratification for elderly patients. Dysregulation of the metabolic pathways revealed in this study may aid in the drug and vaccine development against COVID-19. Frontiers Media S.A. 2021-01-07 /pmc/articles/PMC7873923/ /pubmed/33585504 http://dx.doi.org/10.3389/fmed.2020.595503 Text en Copyright © 2021 Mei, Wang, Bryant, Yang, Li, Wang, Du, Kurts, Wu, Ma, Wu, Chen, Luo, Li, Hu, Yuan and Li. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Mei, Qi
Wang, Amanda Y.
Bryant, Amy
Yang, Yang
Li, Ming
Wang, Fei
Du, Shangming
Kurts, Christian
Wu, Patrick
Ma, Ke
Wu, Liang
Chen, Huawen
Luo, Jinlong
Li, Yong
Hu, Guangyuan
Yuan, Xianglin
Li, Jian
Survival Factors and Metabolic Pathogenesis in Elderly Patients (≥65) With COVID-19: A Multi-Center Study
title Survival Factors and Metabolic Pathogenesis in Elderly Patients (≥65) With COVID-19: A Multi-Center Study
title_full Survival Factors and Metabolic Pathogenesis in Elderly Patients (≥65) With COVID-19: A Multi-Center Study
title_fullStr Survival Factors and Metabolic Pathogenesis in Elderly Patients (≥65) With COVID-19: A Multi-Center Study
title_full_unstemmed Survival Factors and Metabolic Pathogenesis in Elderly Patients (≥65) With COVID-19: A Multi-Center Study
title_short Survival Factors and Metabolic Pathogenesis in Elderly Patients (≥65) With COVID-19: A Multi-Center Study
title_sort survival factors and metabolic pathogenesis in elderly patients (≥65) with covid-19: a multi-center study
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873923/
https://www.ncbi.nlm.nih.gov/pubmed/33585504
http://dx.doi.org/10.3389/fmed.2020.595503
work_keys_str_mv AT meiqi survivalfactorsandmetabolicpathogenesisinelderlypatients65withcovid19amulticenterstudy
AT wangamanday survivalfactorsandmetabolicpathogenesisinelderlypatients65withcovid19amulticenterstudy
AT bryantamy survivalfactorsandmetabolicpathogenesisinelderlypatients65withcovid19amulticenterstudy
AT yangyang survivalfactorsandmetabolicpathogenesisinelderlypatients65withcovid19amulticenterstudy
AT liming survivalfactorsandmetabolicpathogenesisinelderlypatients65withcovid19amulticenterstudy
AT wangfei survivalfactorsandmetabolicpathogenesisinelderlypatients65withcovid19amulticenterstudy
AT dushangming survivalfactorsandmetabolicpathogenesisinelderlypatients65withcovid19amulticenterstudy
AT kurtschristian survivalfactorsandmetabolicpathogenesisinelderlypatients65withcovid19amulticenterstudy
AT wupatrick survivalfactorsandmetabolicpathogenesisinelderlypatients65withcovid19amulticenterstudy
AT make survivalfactorsandmetabolicpathogenesisinelderlypatients65withcovid19amulticenterstudy
AT wuliang survivalfactorsandmetabolicpathogenesisinelderlypatients65withcovid19amulticenterstudy
AT chenhuawen survivalfactorsandmetabolicpathogenesisinelderlypatients65withcovid19amulticenterstudy
AT luojinlong survivalfactorsandmetabolicpathogenesisinelderlypatients65withcovid19amulticenterstudy
AT liyong survivalfactorsandmetabolicpathogenesisinelderlypatients65withcovid19amulticenterstudy
AT huguangyuan survivalfactorsandmetabolicpathogenesisinelderlypatients65withcovid19amulticenterstudy
AT yuanxianglin survivalfactorsandmetabolicpathogenesisinelderlypatients65withcovid19amulticenterstudy
AT lijian survivalfactorsandmetabolicpathogenesisinelderlypatients65withcovid19amulticenterstudy